Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Lymphoma, Mantle-Cell × ibrutinib × Clear all

Status

Completed 30 Active not recruiting 11 Withdrawn 6 Unknown 4 Terminated 4 Recruiting 4 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Lymphoma, Mantle-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pirtobrutinib 1 ibrutinib 1 fludarabine 1 brexucabtagene autoleucel 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01833039 2025-02-03

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Janssen Biotech, Inc.

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡